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Background: People who inject drugs (PWID) do so at varying frequencies. More frequent injecting 17 
is associated with skin and soft tissue infection, blood borne viruses, and overdose. The aims of this 18 
review are to estimate the prevalence of injecting frequency among PWID and compare these 19 
estimates to current needle-syringe distribution coverage estimates, and identify socio-demographic 20 
and risk characteristics, and harms associated with daily or more injecting. 21 
Methods: We conducted a systematic review of the peer-reviewed and grey literature from 2008 to 22 
2018 and extracted needle-syringe distribution coverage data from a recent systematic review. We 23 
generated country-, region-, and global-level estimates of daily or more injecting. We also ran meta-24 
regression analyses to determine associations between daily or more injecting and socio-demographic 25 
characteristics, injecting risk behaviour, non-fatal overdose, injection site skin infection, and blood 26 
borne virus prevalence. 27 
Results: Our search resulted in 61,077 sources, from which 198 studies were eligible for inclusion in 28 
this review. There were 74 countries with estimates for injecting frequency. Globally, we estimated 29 
that 68.1% (95%CI 64.5, 71.6%) of PWID, equating to approximately 10.5 (95% UI 6.8-15.0) million 30 
people, inject daily or more frequently. There was a higher percentage of participants reporting daily 31 
or more injecting among samples with shorter injecting careers, more male participants and higher 32 
reporting of opioids as their main drug injected. Daily or more injecting was also associated with 33 
samples reporting a higher prevalence of HIV and hepatitis C antibody (anti-HCV), non-fatal 34 
overdose, and receptive needle sharing in the previous month. 35 
Implications: WHO recently recommended a needle-syringe distribution target of 300 needles per 36 
PWID per year which is unlikely to be sufficient for the majority of PWID injecting daily or more 37 
who are out of drug treatment.  38 
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Globally, there are an estimated 15.6 million people who inject drugs (PWID) (Degenhardt et al., 45 
2017). People who inject do so at varying frequencies. More frequent injecting has been associated 46 
with higher-risk injecting practices such as re-using and sharing injecting equipment and injecting into 47 
the neck and femoral vein (Darke, Swift, Hall, & Ross, 1994; Rafful et al., 2015; Tarján et al., 2015; 48 
Wilson, Brener, Mao, & Treloar, 2014), which also increases risk of severe harms such as blood borne 49 
viral infections and thrombophlebitis (Corneil et al., 2006; Miller et al., 2006; Rafful et al., 2015; 50 
Schoenbaum et al., 1989; Todd et al., 2011). More frequent injecting is also independently associated 51 
with several health harms including injection site skin infection and overdose (Blackburn et al., 2017; 52 
Brugal et al., 2002; Kinner et al., 2012; Lafferty, Smith, Coull, & Shanley, 2016; Larney, Peacock, 53 
Mathers, Hickman, & Degenhardt, 2017; Noroozi et al., 2018; Robinson et al., 2017).  54 
Multiple factors may contribute to the variation in injecting frequency. For example, PWID with 55 
longer injecting careers who have an increased tolerance, or are transitioning from experimental drug 56 
use to dependence, may be injecting higher doses but also more frequently (National Institute on Drug 57 
Abuse, 2007). Similarly, drug type can mediate injecting behaviour; relative to an opiate, cocaine has 58 
a short half-life (approximately 30 minutes) and therefore injecting may occur more frequently in 59 
order to sustain a high (Korsmeyer & Kranzler, 2009; van Beek, Dwyer, & Malcol, 2001). In contrast, 60 
PWID in opioid agonist treatment (OAT) typically inject less frequently than those out of treatment 61 
(Mattick, Breen, Kimber, & Davoli, 2009; Platt et al., 2018; Scott, Caulkins, Ritter, & Dietze, 2015). 62 
As well as individual factors, local societal factors can also contribute to variation in injecting 63 
frequency. These might include drug market characteristics and drug policy that govern the 64 
availability of different drug types and the provision of drug treatment and other harm reduction 65 
services (Day, Degenhardt, Gilmour, & Hall, 2004; MacArthur et al., 2012).  66 
Measuring injecting frequency is important for informing harm reduction services, such as needle and 67 
syringe programs (NSPs). NSPs distribute sterile injecting equipment to PWID and are an important 68 
part of the global response to reduce the transmission of blood borne viruses. The World Health 69 




to improve coverage and reduce the transmission of blood borne virus infection; however, this target 71 
assumes less than daily frequency of injecting for PWID. Identifying frequency of injecting across 72 
countries is critical to understand sufficiency of this target distribution, yet to our knowledge there has 73 
been no systematic review of frequency of injecting by country and globally. Therefore, we aimed to: 74 
o Estimate country, regional, and global-level injecting frequency among PWID; 75 
o Identify socio-demographic and injecting characteristics associated with frequency of 76 
injecting among PWID; 77 
o Evaluate the associations between frequency of injecting and engaging in injecting 78 
risk behaviour, non-fatal overdose, HIV prevalence, hepatitis C antibody (anti-HCV) 79 
prevalence and recent skin and soft tissue infection; and  80 
o Compare country-level injecting frequency estimates to country-level NSP coverage. 81 





Data source 84 
Data for this review comes from a broader systematic review investigating prevalence of injecting, 85 
socio-demographic and risk characteristics of PWID (defined henceforth as people who have injected 86 
drugs within the previous year), and blood borne virus prevalence among PWID globally (Degenhardt 87 
et al., 2017). The review protocol is registered with PROSPERO (record number CRD42016052853) 88 
and reported according to PRISMA (Moher, Liberati, Tetzlaff, Altman, and The (2009); Appendix 1) 89 
and GATHER guidelines (Stevens et al. (2016); Appendix 2). In 2016, peer-reviewed literature 90 
(Medline, Embase, and PsycINFO), grey literature and online databases were systematically searched, 91 
and data requests were sent to international experts and agencies for literature published from 2008 92 
onwards. Peer-reviewed literature searches were updated in June 2017 and July 2018. We searched 93 
for sources with estimates of injecting drug use (IDU) prevalence, characteristics of PWID including 94 
socio-demographic and risk characteristics, frequency of injecting, injecting-related injuries and 95 
diseases, and serologically confirmed blood borne virus prevalence. Search terms included keywords 96 
with explosions of terms for IDU and epidemiology, IDU and HIV, and IDU and infections 97 
(Appendix 3 and 4). 98 
Screening and study selection 99 
Two researchers independently screened studies for inclusion, and all conflicts were resolved in 100 
discussion or consultation with a third researcher. Data were extracted into a Microsoft Access 101 
Database, and exported and cleaned in Microsoft Excel. Where there were multiple studies reporting 102 
on the same sample, the study with the most complete information was included. In the current 103 
review, studies with data on frequency of injecting by PWID (self-report) were included, unless: a) 104 
there were fewer than 40 (PWID) participants in the sample, b) the sample was a subpopulation (e.g. 105 
samples of PWID who were HIV-positive or incarcerated), c) the inclusion criteria specified daily (or 106 
more frequent) injecting, d) the most frequent category for injecting was monthly or more (or less 107 
frequent), e) the study was an earlier iteration of a more recent study, or f) there was an age restriction 108 





Frequency of injecting was extracted as categorised in the source and then coded to our definitions to 111 
create consistency across studies (the definitions are provided in Appendix 5). We originally intended 112 
on presenting the data in the detailed categories defined in Appendix 5; however, frequency categories 113 
and definitions varied greatly between studies. These broader definitions were therefore combined to 114 
create binary ‘daily or more’ and ‘less than daily’ estimates for each study. We based our definitions 115 
on the most commonly reported injecting frequency categories. Several studies did not conform to our 116 
definitions of injecting frequency, and our decision process for including studies in our analyses is 117 
reported in Appendix 6.  118 
There were nine study-level exposure variables that we aimed to investigate: year of data collection; 119 
median (or mean if median was not reported) duration of injecting (in years); and self-report 120 
proportion of the sample that were female, young (defined as ≤25 years), reported current engagement 121 
in opioid agonist treatment (OAT), opioids as their main drug injected, stimulants as their main drug 122 
injected, unstable housing or homelessness within the previous 12 months, and incarceration within 123 
the previous 12 months. Region and country-level income class (low, lower-middle, upper-middle, 124 
and high) (World Bank, 2018) were also extracted into the dataset. 125 
Considering frequency of injecting as the predictor variable, there were also five outcome variables 126 
we aimed to investigate: the proportion of participants engaging in recent risky injecting behaviour 127 
(defined as receptive needle or syringe sharing in the previous month); serologically confirmed HIV 128 
and anti-HCV prevalence; self-reported non-fatal overdose in the previous 12 months; and self-129 
reported skin and soft tissue infection (in the previous 12 months). 130 
Data analysis 131 
 Estimates of injecting frequency by country 132 
To create frequency of injecting estimates among PWID by country we drew on methods used in 133 
previous reviews (Degenhardt et al., 2017). Eligible injecting frequency estimates were selected and, 134 




analysis models in STATA using the metaprop command. To create estimates that were the most 136 
temporally relevant, we included all estimates that were within 5 years of the most recent estimate. To 137 
generate the estimated number of PWID based on the daily or more and less than daily estimates, we 138 
multiplied the prevalence of IDU (as reported in Degenhardt et al. (2017)) by the proportion reporting 139 
daily or more and less than daily injecting. The product was multiplied by the country’s adult 140 
population aged 15-64 years as of 2015 (UN Population Division, 2016). We estimated 95% 141 
uncertainty intervals (UIs) using Monte Carlo simulation taking 100,000 draws. We used a binomial 142 
distribution because our parameters of interest were proportions (the products of IDU proportion 143 
among population and frequency proportions among PWID). Estimated sample sizes were derived 144 
from the 95% UIs and standard errors of the proportion estimates for each country. 145 
 Estimates of injecting frequency by region 146 
Countries were grouped according to UNAIDS, WHO and United Nations Office on Drugs and Crime 147 
regions. We computed region-specific, weighted estimates of injecting frequency using all the 148 
observed estimates and 95% UI of estimates in each country within that region and deriving a 149 
weighted estimate and UI, based on country population size. Where regions had one (or zero) country 150 
with an estimate (unless that country accounted for >50% of the region population), the global 151 
estimate was imputed for the countries with evidence of IDU but without an injecting frequency 152 
estimate. Otherwise, the regional estimate was imputed. We used these regional estimates to estimate 153 
the global prevalence of daily or more and less than daily injecting.  154 
 Evaluating associations between daily or more injecting and study-level characteristics 155 
We examined the study-level association between socio-demographic variables and daily or more 156 
injecting and, in turn, daily or more injecting and negative health outcomes. Using meta-regression 157 
analysis in STATA 15, we first built models for the 10 predictor variables and daily or more injecting 158 
as the outcome variable, adjusting for region. We conducted the same analyses with daily or more 159 
injecting as the predictor variable, and HIV prevalence, anti-HCV prevalence, proportion reporting 160 




excluded predictor variables from this analysis that were available for fewer than 25% of the total 162 
studies. Thus, self-reported engagement in OAT, stimulants as their main drug injected, recent 163 
incarceration, and skin and soft tissue infections were excluded from the analyses.  164 
Injecting frequency and NSP coverage 165 
To compare estimated percentages of daily or more injecting and NSP coverage by country we used 166 
Tableau 2018.2. Using country-level estimates for daily or more injecting from this study and 167 
country-level NSP coverage data (specifically, estimated number of needles and syringes distributed 168 
per PWID per year for 2015) drawn from Larney, Peacock, Leung, et al. (2017) we presented data for 169 
countries that had an estimate for both variables.  170 





Our search resulted in 61,077 sources, from which 198 studies were eligible for inclusion in this 173 
review (flowchart presented in Appendix 7). Of 179 countries with recorded evidence of injecting, 174 
there were 74 countries that had one or more estimates of injecting frequency. The studies covered 175 
data collected from 1997 to 2017; over a third of the samples were from studies that specifically 176 
recruited participants who had injected in the previous month. Recruitment criteria for recency of 177 
injecting, study and method grade, and other study-level characteristics are presented in Appendix 8.  178 
Regional and global estimates for frequency of injecting are displayed in Table 1. Globally, we 179 
estimated that 68.1% (95% CI 64.5-71.6%) of PWID, equating to approximately 10.5 (95% UI 6.8-180 
15.0) million people, inject daily or more frequently. Latin America (95.0%; 95%CI 93.4, 96.1%), 181 
South Asia (85.2%; 95%CI 81.8, 89.0%), and East and Southeast Asia (86.3%; 95%CI 84.6, 88.0%) 182 
had the highest estimated percentage of daily or more injecting, and Eastern Europe had the lowest 183 
percentage (41.8%; 95%CI 38.3, 45.3%). 184 
< Table 1 here > 185 
Figure 1 displays a map of grouped country-level estimates of daily or more injecting. Existing 186 
studies suggest that Pakistan (100.0%; 95% CI 99.7-100.0%), Colombia (99.8%; 95% CI 99.0-187 
100.0%), Romania (99.7%; 99.2-100.0%), and Viet Nam (98.6%; 95% CI 98.0-99.1%) had the 188 
highest percentage reporting daily or more injecting, while Georgia (2.1%; 95% CI 0.8-3.4%), Taiwan 189 
(4.9%; 95% CI 2.7-8.1%) and Moldova (8.9%, 95% CI 0.8-17.1%) had the lowest. All country-level 190 
estimates are presented in Table 2. Definitions and frequency estimates by study are presented in 191 
Appendix 9.  192 
< Figure 1 here > 193 
< Table 2 here > 194 
Table 3 presents the results of the univariable and multivariable meta-regression analyses with daily 195 
or more injecting as the outcome variable and socio-demographic characteristics and income-class as 196 




injected (meta-regression coefficient [β]=0.47; 95% confidence intervals [CI] 0.23, 0.71, p<0.001) 198 
and studies from low- and middle-income class countries (β=0.03; 95%CI 0.03, 0.15, p=0.004) were 199 
associated with higher levels of daily or more injecting. Longer average duration of injecting (β=-0.02 200 
per year; 95%CI -0.03, -0.01, p<0.001), more recent calendar period (β=-0.01 per year; 95%CI -0.02, 201 
0.00, p=0.009), and a higher proportion of female PWID in the sample (β=-0.20; 95%CI -0.37, -0.02, 202 
p=0.032) were associated with lower levels of daily or more injecting; however, after adjusting for 203 
region there was no longer a relationship between proportion of female PWID in the sample (β=-0.05; 204 
95%CI -0.22, 0.12, p=0.551) or income-class (β=0.03; 95%CI -0.07, 0.13), p=0.530) and daily or 205 
more injecting. There was no evidence that the proportion of the sample who were young, or who had 206 
recently experienced unstable housing were associated with level of daily or more injecting. 207 
Scatterplots displaying the results of the meta-regression analyses are presented in Appendix 10. 208 
< Table 3 here > 209 
< Table 4 here > 210 
Daily or more injecting was associated with a range of study-level behaviours and health outcomes, 211 
both univariable and multivariable results are presented in Table 4. There were associations between 212 
level of daily or more injecting in the sample and proportion of the sample reporting recent receptive 213 
needle sharing (β=0.31; 95%CI 0.19, 0.43, p<0.001) and non-fatal overdose in the past 12 months 214 
(β=0.18; 95%CI 0.09, 0.27, p<0.001), and the prevalence of HIV (β=0.17; 95%CI 0.09, 0.25, 215 
p<0.001) and anti-HCV (β=0.25; 95%CI 0.12, 0.37, p<0.001) in the sample.  216 
< Figure 2 here > 217 
Figure 2 presents the available country-level daily or more injecting estimates with their 218 
corresponding country-level NSP coverage. There were 48 countries where both estimates were 219 
available. Country NSP coverage estimates clustered close to zero, including many of the countries 220 
reporting more frequent injecting. Figure 3 displays the same information for the top 25 countries by 221 
estimated number of PWID. The United States, China and Russia held over a third of the global IDU 222 




< Figure 3 here > 224 
Discussion 225 
We estimated that the majority of PWID injected daily or more (68.1%; 95% CI: 64.5-71.6%), 226 
equating to over 10 million people. In Europe, the Middle East and North Africa sampled PWID were 227 
more likely to inject less than daily. Higher levels of daily or more injecting were associated with 228 
higher prevalence of receptive needle-syringe sharing, HIV and anti-HCV prevalence, as well as 229 
higher levels of non-fatal overdose in the previous year. Notably, among countries with higher 230 
estimates of daily or more injecting, there was very low NSP coverage reported for 2015 (Larney, 231 
Peacock, Leung, et al., 2017). 232 
There is inconsistency across studies in definitions of injecting frequency. These differences may be 233 
arbitrary, or they may be region specific, inasmuch as frequency definitions used by researchers in 234 
different countries or regions may be decided based on previously observed injecting behaviour. For 235 
example, two of the three included studies from Tehran, Iran, asked participants whether they were 236 
injecting one to three, three to six, or more than six times a day, suggestive of local knowledge of 237 
pervasive high-frequency injecting among PWID (Asli, Kandelouei, Rahimyan, Davoodbeglou, & 238 
Vaezjalali, 2016; Kandelouei et al., 2013). Frequency definitions may also differ according to 239 
research questions or aims. For instance, the Australian Illicit Drug Reporting System aimed to recruit 240 
participants with knowledge of recent drug trends. As a result, the inclusion criteria comprised at least 241 
monthly injections in the previous six months (Peacock et al., 2018). The variability of frequency of 242 
injecting variables between research studies complicates investigating and comparing injecting 243 
behaviour geographically. 244 
To our knowledge, this is the first systematic review of frequency of injecting among PWID, which 245 
has generated estimates of global, regional and country-level frequency of injecting among PWID. 246 
There are, however, several limitations. Firstly, survey data may be inherently biased towards people 247 
who inject more frequently, and therefore is not necessarily an accurate representation of the entire 248 
PWID population. Although recruitment techniques such as respondent driven and snowball sampling 249 




harm reduction services such as NSPs and drop in centres. Surveys recruiting from such services are 251 
likely to sample PWID with more frequent injecting (Brienza et al., 2000), while other service-based 252 
recruitment (e.g. drop in centres) may exclude particularly marginalised populations, or people 253 
concerned about being identified as someone who injects drugs. To reduce the risk of bias we 254 
excluded all studies that specified daily or more frequent injecting in the inclusion criteria; however, 255 
that does not eliminate inherent bias in recruitment strategies. Our results found that studies from five 256 
countries reported estimates of >98.0% for daily or more injecting, and it is difficult to determine 257 
whether the estimates are an accurate reflection of the injecting behaviour among PWID in that 258 
country or whether recruitment of participants was conducted such that people who inject more 259 
frequently were overrepresented.  260 
Second, frequency data is typically reported categorically, and we were unable to calculate point 261 
estimates. Thus, there is limited detail to compare needle-syringe distribution coverage estimates to a 262 
more specific injecting frequency. Further, the results of this review do not reflect, and cannot discern 263 
between, regular and episodic injecting, including so-called “binge” patterns of injecting (i.e. high 264 
intensity IDU that differs from typical injecting practices). Binge injecting is independently associated 265 
with injecting risk behaviour, abscess wounds, non-fatal overdose and HIV transmission (Kerr et al., 266 
2007; Kinner et al., 2012; Miller et al., 2006; van Beek et al., 2001; Van Hout & Bingham, 2012); 267 
however, might represent a sub-population of people who are injecting frequently. 268 
Third, our regional and global estimates of the proportion of PWID engaging in daily or more 269 
injecting are limited by the country-level frequency data that is available. Of the 74 countries with 270 
frequency of injecting data, 47 (64%) country estimates were based on data from a single source, and 271 
34 (46%) country estimates were based on a single estimate (compared to multiple estimates from the 272 
same source). The frequency estimates reported for Sri Lanka, Croatia, and Switzerland are 273 
presumably over-estimated (as they capture PWID who are injecting less frequently than ‘daily or 274 
more’) and Israel, Palestine, Afghanistan and Sweden are presumably under-estimated. We conducted 275 
a sensitivity analysis (presented in Appendix 11) excluding those seven countries and found that the 276 




with the estimates presented in Table 1. The exception was the Middle East and North African 278 
regional estimate which, although overlapped, was much lower in the sensitivity analysis (47.3% 279 
[95%CI 42.0-52.7%] and 38.5% [95%CI 33.6-43.6%]). We would assume the three country-level 280 
estimates from this region are an underestimate of the “true” frequency estimates according to our 281 
definition. Therefore, we concluded that our presented findings are a more accurate representation of 282 
the available data. 283 
Some regional estimates were informed by very little empirical evidence. Notably, regional estimates 284 
for the Caribbean, Latin America and Central Asia are driven by only four studies from four 285 
countries: Puerto Rico, Chile, Mexico, and Tajikistan; none of which are nationally representative. 286 
Figure 1 is a clear visualisation that highlights the need for good quality surveillance data that recruits 287 
PWID from multiple sites and covers a wider geography. National, regional and global estimates of 288 
the epidemiology of IDU and associated behaviours and characteristics are important for informing 289 
drug and harm reduction policy; however, for informative surveillance estimates to be generated there 290 
needs to be higher quality studies conducted in these missed regions where there is evidence of 291 
injecting. 292 
While investigating the prevalence of daily or more injecting at a national level is informative, there is 293 
much sub-national variation in injecting behaviours within countries. For example, the report 294 
informing the country-level estimate for the Philippines has data from four sites, and daily or more 295 
injecting ranged from 4.0% in Zamboanga to 90.0% in Cebu (HIV and AIDS Data Hub for Asia-296 
Pacific, 2011). The report from Azerbaijan reported similar sub-national variation, with 18.0% 297 
reporting daily or more injecting in Masalli whereas 91.0% reported daily or more injecting in Baku 298 
(Ministry of Health the Republic of Azerbaijan, 2008). 299 
Finally, the meta-regression results may be subject to ecological fallacy, in that sample averages 300 
across studies may not be the same as the association for participants within a study (Thompson & 301 
Higgins, 2002). Relationships are more easily interpreted when there is high variation across studies 302 
compared to within studies. Therefore, the results of the meta-regression analyses should be 303 




There may be many factors that influence the current and future frequency at which PWID are 305 
injecting. Firstly, drug market trends may limit the supply of certain drugs while increasing the 306 
availability of others. A recent example of this is the widespread cathinone injection among PWID in 307 
Hungary and Romania, and increasingly so in parts of Ireland and Scotland, resulting in binge and 308 
high frequency injection (Lafferty et al., 2016; McAuley et al., 2019; Rácz et al., 2016; Tarján et al., 309 
2015). There is also evidence for the opposite relationship, in so much that the unavailability of 310 
certain drug types results in less frequent injecting (Day et al., 2004). Similarly, PWID in treatment, in 311 
hospital or in recovery may not be injecting as frequently or at all. The appearance of abscess wounds 312 
motivates some people to reduce their injecting to allow the wound to heal (Dunleavy, Hope, Roy, & 313 
Taylor, 2019), potentially moderating the relationship between skin and soft tissue infection and 314 
frequency of injecting. Treatment engagement may also influence injecting frequency, which has been 315 
repeatedly shown for PWID engaged in OAT. Demonstrated in a recent cohort of PWID was that 316 
those on OAT were injecting 35% less frequently than those not on OAT (Scott et al., 2015).  317 
These findings have important implications for harm reduction services that supply needles, syringes 318 
and other injecting equipment. The WHO recently increased “high” NSP coverage from ≥200 to ≥300 319 
needles per PWID per year (World Health Organization (WHO), 2016). Considering there is an 320 
estimated 33 needle-syringes distributed per PWID per year and 16 OAT recipients per 100 PWID 321 
globally, current coverage is clearly far from satisfactory. Further, in countries with the highest 322 
estimated percentages of daily or more injecting there was very poor or no NSP coverage. However, 323 
even in Australia, where NSP coverage is ‘high’ and frequency of injecting is moderate, a recent 324 
estimate determined sufficient coverage to be when 550 syringes were distributed per PWID per year 325 
(Kwon et al., 2019), almost double the WHO recommendation. Insufficient needle and syringe 326 
distribution coverage is associated with PWID reusing their own needles and sharing injecting 327 
equipment which can lead to blood borne virus transmission, bacterial infections, and vein damage 328 
(Bluthenthal, Anderson, Flynn, & Kral, 2007; O’Keefe et al., 2018; Tarján et al., 2015). Our review 329 
offers a foundation to inform more robust and country specific NSP coverage targets based on actual 330 




Our results represent a broad picture of injecting patterns among PWID globally and indicate that the 332 
majority of PWID are injecting daily or more frequently. Understanding injecting frequency is 333 
important for informing adequate NSP coverage, and we highlight the need for better surveillance 334 
data to achieve this. There is poor availability of surveillance data from many parts of the world, 335 
particularly lower socioeconomic and vulnerable populations. Finally, evidence-based harm reduction 336 
programs must be nuanced and responsive to the local drug market in order to effectively reduce the 337 
risk of harms this population is vulnerable to. 338 
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Figure 2: Daily or more injecting estimates and needle-syringe distribution coverage by country 
 




Figure 3: Estimated number of people who are injecting daily or more and needle-
syringe distribution coverage for the 25 countries with the largest number of people 






























Table 1: Frequency of injecting among people who inject drugs (PWID) by region 
 Region Countries with data 






% (95% CI) 
Number of PWID who are 
injecting daily or more 




% (95% CI) 
Number of PWID who are 
injecting less than daily 
N (95% UI) 
Eastern Europe 16/17 41.8 (38.3-45.3) 1,262,500 (647,000-1,984,000) 58.2 (54.7-61.7) 1,757,500 (817,500-2,861,000) 
Western Europe 17/33 45.1 (40.8-49.5) 455,500 (321,500-622,000) 54.9 (50.5-59.2) 554,000 (361,000-784,500) 
East and Southeast Asia 10/17 86.2 (84.5-88.0) 3,440,000 (2,631,500-4,296,500) 13.7 (12.0-15.4) 548,000 (410,500-702,000) 
South Asia 8/9 85.2 (81.1-89.0) 871,500 (678,500-1,081,500) 14.7 (11.2-18.3) 150,000 (92,000-219,000) 
Central Asia 3/5 64.0 (60.1-67.9) 180,000 (110,000-258,500) 36.0 (32.2-39.8) 101,500 (61,000-147,000) 
Caribbean 1/15 73.1 (69.0-76.8) 58,000 (35,000-83,000) 26.9 (23.2-30.9) 21,500 (12,500-31,000) 
Latin America 2/20 95.0 (93.4-96.1) 1,731,500 (1,276,500-2,218,000) 5.0 (4.0-6.4) 92,000 (61,000-129,000) 
North America 2/2 65.1 (57.8-72.4) 1,544,500 (657,000-2,595,000) 34.9 (27.6-42.2) 827,000 (364,500-1,401,000) 
Pacific Island states & terr. 0/17 NK NK NK NK 
Australasia 2/2 50.3 (45.0-55.6) 58,000 (41,500-76,500) 49.4 (44.2-54.6) 57,000 (40,500-75,000) 
Sub-Saharan Africa 7/47 54.2 (50.3-58.0) 747,500 (262,000-1,467,000) 45.8 (42.1-49.7) 631,000 (135,500-1,358,500) 
Middle East & North Africa 6/22 47.3 (42.0-52.7) 165,500 (88,000-255,000) 52.7 (47.3-58.0) 184,000 (98,000-283,500) 
Global  74/206 68.1 (64.5-71.6) 10,529,000 (6,757,000-14,958,000) 31.9 (28.4-35.4) 4,930,500 (2,459,000-8,002,500) 





Table 2: Country-level estimates of frequency of injecting among people who inject 
drugs (PWID) 
 Daily or more injecting Less than daily injecting 









    
Armenia                             36.9 (15.8-58.0) 5,000 (1,500-10,000) 63.1 (42.0-84.2) 8,500 (2,500-16,000) 
Azerbaijan                          48.5 (23.1-73.8) 21,000 (13,500-29,500) 51.5 (26.2-76.9) 22,500 (14,500-31,000) 
Belarus                             34.4 (19.3-49.5) 14,000 (5,000-26,500) 65.5 (50.4-80.6) 26,500 (11,000-47,000) 
Bosnia & 
Herzegovina                
20.3 (7.9-32.7) 7,000 (2,500-14,000) 79.7 (67.3-92.1) 27,500 (13,000-45,000) 
Bulgaria                            84.4 (81.8-86.7) 15,500 (12,500-19,000) 15.7 (13.3-18.2) 3,000 (2,000-3,500) 
Czech Republic                      87.2 (83.8-90.2) 41,000 (38,500-43,500) 12.8 (9.9-16.2) 6,000 (4,500-7,500) 
Estonia                             29.0 (20.6-37.3) 2,500 (1,000-4,500) 71.0 (62.7-79.4) 6,000 (3,000-10,000) 
Georgia 2.1 (0.8-3.4) 2,500 (500-5,500) 97.8 (96.6-99.1) 112,500 (24,000-217,000) 
Hungary                             43.3 (39.8-46.8) 1,500 (1,000-2,500) 56.7 (53.2-60.2) 2,500 (1,000-3,500) 
Latvia                              28.3 (24.9-31.6) 4,000 (3,000-5,000) 71.7 (68.4-75.1) 10,000 (7,500-12,500) 
Lithuania                           76.3 (71.8-80.3) 3,500 (2,000-6,000) 23.8 (19.7-28.2) 1,000 (500-2,000) 
Moldova                             8.9 (0.8-17.1) 1,000 (<500-2,500) 91.1 (82.9-99.3) 11,000 (7,000-15,500) 
Poland                           84.6 (81.8-87.1) 307,000 (149,000-489,000) 15.4 (12.9-18.2) 56,000 (26,500-91,500) 
Romania                             99.7 (99.2-100.0) 81,000 (57,500-107,000) 0.2 (0.0-0.5) <500 (<500-500) 
Russia                    36.0 (32.7-39.4) 677,000 (324,500-1,087,500) 64.0 (60.6-67.3) 1,204,000 (582,500-
1,919,000) 
Slovakia                            NK NK NK NK 
Ukraine 22.0 (21.3-22.7) 70,500 (31,000-119,500) 78.0 (77.3-78.7) 249,000 (111,500-422,000) 
Western Europe 
    
Albania 65.5 (58.5-72.1) 4,500 (3,000-6,000) 34.5 (27.9-41.5) 2,500 (1,500-3,500) 
Andorra NK NK NK NK 
Austria 59.7 (46.5-72.0) 11,000 (7,000-15,500) 40.3 (28.1-53.6) 7,500 (4,500-11,000) 
Belgium 43.4 (36.7-50.2) 11,500 (7,000-16,000) 56.6 (49.8-63.3) 15,000 (9,500-21,000) 
Croatia 34.7 (0.0-76.9) 2,000 (1,000-3,500) 65.3 (23.1-100.0) 4,000 (3,000-5,500) 
Denmark NK NK NK NK 
England 52.5 (51.1-54.0) 110,500 (102,500-119,000) 47.5 (46.0-48.9) 100,000 (92,500-107,500) 
Finland NK NK NK NK 
France NK NK NK NK 
Macedonia NK NK NK NK 
Germany 24.4 (20.2-28.6) 32,000 (6,500-65,000) 75.6 (71.4-79.8) 99,500 (20,500-200,000) 
Greece 37.9 (36.3-39.6) 2,000 (1,500-2,500) 61.9 (60.2-63.5) 3,000 (2,500-4,000) 
Iceland NK NK NK NK 
Ireland 51.3 (45.6-56.9) 4,500 (3,000-5,500) 48.7 (43.1-54.4) 4,000 (3,000-5,500) 
Italy NK NK NK NK 
Luxembourg NK NK NK NK 
Malta NK NK NK NK 
Monaco NK NK NK NK 
Montenegro 47.0 (43.2-50.9) 500 (500-1,000) 53.0 (49.1-56.8) 1,000 (500-1,000) 
Netherlands NK NK NK NK 
Northern Ireland 52.5 (51.1-54.0) 3,500 (1,500-5,500) 47.5 (46.0-48.9) 3,000 (1,500-5,000) 
Norway 61.6 (59.9-63.3) 5,000 (4,500-6,000) 38.5 (36.7-40.2) 3,000 (2,500-4,000) 
Portugal NK NK NK NK 
San Marino NK NK NK NK 
Scotland 46.3 (42.2-50.4) 7,500 (6,000-8,500) 53.7 (49.7-57.8) 8,500 (7,500-10,000) 
Serbia 46.9 (42.6-51.2) 13,500 (11,000-16,500) 53.1 (48.8-57.4) 15,500 (12,500-18,500) 
Slovenia NK NK NK NK 
Spain 62.2 (35.3-89.2) 6,500 (2,500-11,500) 37.8 (10.8-64.7) 4,000 (1,500-7,500) 
Sweden 81.5 (71.3-89.3) 6,500 (<500-26,500) 18.5 (10.8-28.7) 1,500 (<500-6,000) 
Switzerland 47.9 (44.2-51.6) 6,500 (5,000-8,000) 52.2 (48.4-55.9) 7,000 (5,500-8,500) 
Wales 52.5 (51.1-54.0) 5,500 (2,500-9,500) 47.5 (46.0-48.9) 5,000 (2,500-8,500) 
East and South 
East Asia 
    




 Daily or more injecting Less than daily injecting 








Cambodiaa                            42.0 (33.0-51.4) 4,500 (2,000-7,500) 58.0 (48.6-67.0) 6,000 (2,500-10,500) 
China                               88.6 (87.3-90.0) 2,272,500 (1,753,000-
2,816,000) 
11.4 (10.0-12.7) 291,500 (218,500-373,000) 
Indonesia                           56.8 (55.4-58.3) 108,000 (89,000-128,500) 43.2 (41.7-44.6) 82,000 (67,500-97,500) 
Japan                               NK NK NK NK 
Lao                           61.1 (56.9-65.2) 6,500 (5,000-8,000) 39.1 (35.0-43.3) 4,000 (3,000-5,500) 
Malaysia                            91.1 (89.2-93.0) 256,500 (213,500-302,000) 8.9 (7.0-10.8) 25,000 (18,500-32,500) 
Mongolia                            NK NK NK NK 
Myanmar                             94.1 (91.8-96.3) 163,000 (110,000-222,000) 6.0 (3.7-8.2) 10,500 (5,500-16,500) 
Philippines                         35.1 (0.0-74.1) 9,000 (5,000-14,000) 65.1 (26.3-100.0) 16,500 (11,500-22,500) 
South Korea                   NK NK NK NK 
Singapore                           NK NK NK NK 
Taiwan 4.9 (2.7-8.1) 2,000 (1,000-3,500) 95.1 (92.0-97.3) 43,500 (33,000-54,000) 
Thailanda                            59.8 (55.4-64.2) 31,000 (11,500-54,000) 40.2 (35.8-44.6) 20,500 (7,500-36,500) 
Timor L’Este                         NK NK NK NK 
Viet Nam                            98.6 (98.0-99.1) 158,500 (121,500-198,000) 0.8 (0.4-1.1) 1,000 (500-2,000) 
South Asia 
    
Afghanistan 78.8 (65.8-91.8) 109,500 (68,500-156,500) 21.1 (8.0-34.1) 29,500 (11,500-53,000) 
Bangladesh 96.8 (95.7-97.6) 66,500 (61,500-71,500) 3.3 (2.4-4.3) 2,000 (1,500-3,000) 
Bhutan NK NK NK NK 
India 51.9 (46.9-57.0) 102,500 (66,500-142,000) 47.8 (44.1-51.5) 94,500 (62,000-130,000) 
Iran 98.7 (96.9-100.0) 156,000 (108,500-208,000) 0.6 (0.0-1.9) 1,000 (<500-3,000) 
Maldives 17.6 (13.2-22.1) 500 (-500) 82.4 (77.9-86.8) 1,000 (500-2,000) 
Nepal 39.1 (15.4-62.8) 14,000 (8,500-19,000) 60.9 (37.2-84.6) 21,500 (16,000-27,000) 
Pakistan 100.0 (99.7-100.0) 422,500 (364,000-483,500) 0.0 (0.0-0.2) <500 (<500-500) 
Sri Lanka 19.1 (15.0-23.9) <500 (<500-<500) 80.9 (76.2-85.0) 500 (500-500) 
Central Asia 
    
Kazakhstana                          79.9 (76.2-83.3) 90,000 (55,000-128,500) 20.1 (16.7-23.9) 22,500 (13,500-33,500) 
Kyrgyzstana                        76.7 (72.9-80.3) 22,000 (13,500-31,500) 23.3 (19.7-27.1) 6,500 (4,000-9,500) 
Tajikistan 39.1 (34.8-43.6) 9,000 (5,500-13,500) 60.9 (56.4-65.2) 14,500 (8,500-20,500) 
Turkmenistan                       NK NK NK NK 
Uzbekistan NK NK NK NK 
Caribbean 
    
Bahamas                             NK NK NK NK 
Bermuda                                NK NK NK NK 
Puerto Rico 85.4 (81.0-89.1) 24,000 (14,500-34,500) 14.6 (10.9-19.0) 4,000 (2,500-6,500) 
Dominican Republic                  NK NK NK NK 
Haiti                               NK NK NK NK 
Jamaica NK NK NK NK 
Latin America 
    
Argentina NK NK NK NK 
Bolivia NK NK NK NK 
Brazil NK NK NK NK 
Chile NK NK NK NK 
Colombia 99.8 (99.0-100.0) 153,000 (112,000-196,500) 0.1 (0.0-0.4) <500 (<500-500) 
Costa Rica NK NK NK NK 
Ecuador NK NK NK NK 
El Salvador NK NK NK NK 
Guatemala NK NK NK NK 
Guyana NK NK NK NK 
Honduras NK NK NK NK 
Mexico 90.1 (87.7-92.1) 136,000 (88,500-187,000) 10.1 (8.0-12.5) 15,000 (9,500-22,000) 
Nicaragua NK NK NK NK 
Panama NK NK NK NK 
Paraguay NK NK NK NK 
Peru NK NK NK NK 
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Uruguay NK NK NK NK 
Venezuela NK NK NK NK 
North America 
    
Canada 37.5 (30.6-44.4) 46,000 (34,500-59,000) 62.5 (55.6-69.4) 77,000 (61,000-94,500) 
United States 66.6 (59.3-74.0) 1,498,500 (622,000-
2,536,000) 




    
American Samoa NK NK NK NK 
Federated States of 
Micronesia 
NK NK NK NK 
Fiji NK NK NK NK 
French Polynesia NK NK NK NK 
Guam NK NK NK NK 
Kiribati NK NK NK NK 
Marshall Islands NK NK NK NK 
New Caledonia NK NK NK NK 
Northern Mariana 
Islands 
NK NK NK NK 
Palau NK NK NK NK 
Papua New Guinea NK NK NK NK 
Samoa NK NK NK NK 
Solomon Islands NK NK NK NK 
Tonga NK NK NK NK 
Vanuatu NK NK NK NK 
Australasia 
    
Australia                           51.6 (45.9-57.3) 48,000 (35,000-62,500) 48.1 (42.5-53.6) 44,500 (32,500-58,500) 
New Zealand                         45.0 (41.3-48.7) 10,000 (7,000-13,500) 55.0 (51.3-58.7) 12,500 (8,500-16,500) 
Sub Saharan Africa 
    
Angola NK NK NK NK 
Benina 22.9 (18.8-27.5) 4,000 (1,000-7,500) 77.1 (72.6-81.2) 13,000 (2,500-25,500) 
Burkina Faso NK NK NK NK 
Burundi NK NK NK NK 
Cameroon NK NK NK NK 
Cape Verde NK NK NK NK 
Chad NK NK NK NK 
Cote d'Ivoire NK NK NK NK 
Democratic 
Republic of Congo 
NK NK NK NK 
Djibouti NK NK NK NK 
Ethiopia NK NK NK NK 
Gabon NK NK NK NK 
Gambia NK NK NK NK 
Ghana NK NK NK NK 
Guinea NK NK NK NK 
Kenya 79.9 (74.5-84.5) 24,500 (9,500-43,000) 20.2 (15.5-25.5) 6,000 (2,000-11,500) 
Liberia NK NK NK NK 
Madagascara 4.2 (0.0-8.8) 500 (<500-3,500) 95.8 (91.2-100.0) 15,000 (<500-67,500) 
Malawi NK NK NK NK 
Mali NK NK NK NK 
Mauritius 79.0 (76.5-81.5) 5,500 (1,500-10,000) 21.0 (18.5-23.5) 1,500 (500-2,500) 
Mozambique NK NK NK NK 
Niger NK NK NK NK 
Nigeria 9.8 (4.7-14.9) 26,500 (5,000-60,000) 90.2 (85.1-95.2) 244,000 (49,500-485,000) 
Rwanda NK NK NK NK 
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Seychellesa 46.5 (41.2-51.9) 500 (500-1,000) 53.5 (48.1-58.8) 1,000 (500-1,000) 
Sierra Leone NK NK NK NK 
Somalia NK NK NK NK 
South Africa NK NK NK NK 
Swaziland NK NK NK NK 
Togo NK NK NK NK 
Uganda NK NK NK NK 
Tanzania 86.5 (83.5-89.1) 296,500 (178,500-426,000) 13.6 (11.0-16.5) 46,500 (26,500-70,000) 
Zambia NK NK NK NK 
Zimbabwe NK NK NK NK 
Middle East and 
North Africa 
    
Algeria NK NK NK NK 
Bahrain NK NK NK NK 
Cyprus NK NK NK NK 
Egypt NK NK NK NK 
Iraq NK NK NK NK 
Israel 65.3 (58.3-71.9) 4,000 (2,000-6,000) 34.7 (28.1-41.7) 2,000 (1,000-3,000) 
Jordan NK NK NK NK 
Kuwait NK NK NK NK 
Lebanona 51.9 (40.5-63.1) 2,500 (1,500-4,000) 48.2 (36.9-59.5) 2,500 (1,000-3,500) 
Libya 54.3 (48.7-59.8) 1,000 (500-1,500) 45.7 (40.3-51.3) 1,000 (500-1,500) 
Moroccoa 91.5 (86.9-94.9) 28,000 (14,500-42,500) 8.5 (5.1-13.1) 2,500 (1,000-4,500) 
Palestine 55.6 (51.3-60.0) 2,000 (1,000-2,500) 44.4 (40.0-48.7) 1,500 (500-2,000) 
Oman NK NK NK NK 
Qatar NK NK NK NK 
Saudi Arabia NK NK NK NK 
Sudan NK NK NK NK 
Syria 36.1 (31.3-41.1) 4,500 (2,500-7,000) 63.9 (58.9-68.7) 8,500 (4,500-12,500) 
Tunisia NK NK NK NK 
Turkey NK NK NK NK 
United Arab 
Emirates 
NK NK NK NK 
Yemen NK NK NK NK 
Note. a The estimates for injecting frequency deviated from our definition by 3 injections and were therefore excluded from 
estimating the regional prevalence of frequency. The definitions can be found in Appendix 8.   
NK: There is evidence of injecting in this country but there were no estimates of injecting frequency available.  
For the following countries there is no reported evidence of injecting: (Western Europe) Greenland and Liechtenstein; (East 
and Southeast Asia) North Korea; (Caribbean) Antigua and Barbuda, Barbados, Cuba, Dominica, Grenada, Saint Kitts and 
Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago; (Latin America) Belize; (Pacific Island States 
and Territories) Nauru and Tuvalu; (Sub Saharan Africa) Botswana, Central African Republic, Comoros, Equatorial Guinea, 
Eritrea, Guinea Bissau, Lesotho, Mauritania, Namibia, Republic of the Congo and Sao Tome and Principe; (Middle East and 




Table 3: Univariable and multivariable study-level exposure variables associated with 
daily or more injecting among people who inject drugs 
Study-level exposure variables N Univariable models Multivariable modelse 
βa SEb 95% CIs p β SE 95% CIs p 
Proportion of the sample who are 
female 
269 -0.20 0.09 (-0.37, -0.02) 0.032 -0.05 0.09 (-0.22,0.12) 0.551 
Proportion of the sample reporting 
opioids as main drug injected 
104 0.47 0.12 (0.23, 0.71) <0.001 0.36 0.13 (0.10,0.62) 0.007 
Year of data collection 329 -0.01 0.00 (-0.02, 0.00) 0.009 -0.01 0.00 (-0.02,0.00) 0.033 
Proportion of the sample reporting 
unstable housing/homelessnessc 
111 0.21 0.12 (-0.03, 0.46) 0.085 0.19 0.12 (-0.04,0.43) 0.097 
Proportion of the sample who are 
youngd 
201 0.12 0.10 (-0.08, 0.32) 0.229 -0.09 0.09 (-0.27,0.10) 0.370 
Duration of injecting of the sample 169 -0.02 0.00 (-0.03, -0.01) <0.001 -0.01 0.00 (-0.02,0.00) 0.025 
Income levelf (vs. High-income)          
Low- and middle-income class 329 0.09 0.03 (0.03, 0.15) 0.004 0.03 0.05 (-0.07,0.13) 0.530 
Note. a Meta-regression coefficient 
b Standard error 
c In the previous 12 months 
 d Aged <25 years 
e Adjusted for region 






Table 4: Study-level outcome variables associated with daily or more injecting among 
people who inject drugs 
Study-level outcome variables N Univariable models Multivariable modelse 
βa SEb 95% CIs p β SE 95% CIs p 
Injecting risk behaviourc 124 0.31 0.06 (0.19, 0.43) <0.001 0.34 0.06 (0.21, 0.47) <0.001 
HIV prevalence 218 0.17 0.04 (0.09, 0.25) <0.001 0.18 0.04 (0.09, 0.27) <0.001 
Anti-HCV prevalence 173 0.25 0.06 (0.12, 0.37) <0.001 0.38 0.07 (0.25, 0.50) <0.001 
Non-fatal overdosed 36 0.18 0.04 (0.09, 0.27) <0.001 0.24 0.06 (0.13, 0.36) <0.001 
Note. a Meta-regression coefficient 
b Standard error 
c Self-report receptive sharing of needles and/or syringes in the previous month 
 d Self-reported non-fatal overdose within the previous 12 months 
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